Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTx-265 in Acute Ischemic Stroke
NCT00663416Phase 2Terminated
- Sponsor
- Stem Cell Therapeutics Corp.
- Start
- Mar 2008
- Primary completion
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of human chorionic gonadotropin and epoetin alfa in ischemic stroke (2 arms), sponsored by Stem Cell Therapeutics Corp. Primary endpoints: Modified Rankin Score at Day 90 and National Institutes of Health Stroke Scale Response at Day 90. Started Mar 2008; status: terminated.
02
Drugs
human chorionic gonadotropinepoetin alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00663416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663416.